An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Latest Information Update: 04 Sep 2024
At a glance
- Drugs Alprazolam (Primary)
- Indications Absence epilepsy; Generalised epilepsy; Myoclonic epilepsies; Partial epilepsies; Seizures; Tonic-clonic epilepsy
- Focus Adverse reactions; Registrational
- Sponsors UCB Biopharma
- 30 Aug 2024 Planned End Date changed from 22 May 2026 to 30 Nov 2028.
- 30 Aug 2024 Planned primary completion date changed from 22 May 2026 to 30 Nov 2028.
- 16 May 2023 Planned End Date changed from 22 Aug 2025 to 22 May 2026.